Literature DB >> 2198813

Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations.

P Lardelli1, M A Bookman, J Sundeen, D L Longo, E S Jaffe.   

Abstract

All cases of lymphocytic lymphoma of intermediate differentiation (IDL) referred to the National Cancer Institute were reviewed in order to define the histopathologic spectrum of the disease and to investigate morphologic and immunophenotypic features with potential prognostic relevance. Thirty-three cases were classified as IDL according to histologic criteria. Immunophenotypic analysis was performed in 27 cases, and clinical records were available for 22 patients. The median age was 58 years, and the male-to-female ratio, 3.4:1. All patients presented with stage III or IV disease, and five had extranodal presentations. Median survival was 56.3 months, with only three patients having a prolonged relapse-free survival (greater than 2 years). Morphologically, 14 cases were diffuse or only vaguely nodular; 18 cases showed a mantle zone pattern with naked germinal centers. There was a trend toward prolonged median survival for patients with the mantle zone (77.4 months, p = 0.098). The neoplastic population was composed of irregular or cleaved small lymphoid cells with a mitotic rate ranging from 5 to 62 per 20 high-power fields (hpf). A histologically distinctive variant with blastic cytologic features was identified (seven cases). The blastic variant was associated with a higher mitotic index (51.3 versus 19.0) and shortened survival (24.9 months). In contrast to the histologic progression often observed in follicular lymphomas, in no case was transformation to a large-cell or small noncleaved lymphoma observed. All cases had a mature B-cell phenotype demonstrating monoclonal Ig and B-cell surface antigens. Seventy-eight percent were CD5 positive; three of six CD5-negative cases presented in mucosal-associated extranodal sites. CD10 and CD25 were expressed in 52% and 44%, respectively, but did not show clinical correlations. The proliferative rate measured by Ki-67 positivity correlated with the mitotic index, but neither of these parameters had a statistically significant influence on survival.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2198813     DOI: 10.1097/00000478-199008000-00007

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  22 in total

1.  Parallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practice.

Authors:  Ek Sara; Carl Ak Borrebaeck
Journal:  Curr Genomics       Date:  2007-05       Impact factor: 2.236

Review 2.  Mantle cell lymphoma with a unique pattern of CD5 expression: a case report with review of the literatures.

Authors:  Toshiki Yamada; Naoe Goto; Hisashi Tsurumi; Katsuyoshi Takata; Yasuharu Sato; Tadashi Yoshino; Hisataka Moriwaki; Yusuke Kito; Tamotsu Takeuchi; Hitoshi Iwata
Journal:  Med Mol Morphol       Date:  2013-10-29       Impact factor: 2.309

3.  Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity.

Authors:  P Jares; E Campo; M Pinyol; F Bosch; R Miquel; P L Fernandez; M Sanchez-Beato; F Soler; A Perez-Losada; I Nayach; C Mallofré; M A Piris; E Montserrat; A Cardesa
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

4.  Growth pattern and distribution of follicular dendritic cells in mantle cell lymphoma: a clinicopathological study of 96 patients.

Authors:  Carsten Schrader; Peter Meusers; Günter Brittinger; Dirk Janssen; Afshin Teymoortash; Jens U Siebmann; Reza Parwaresch; Markus Tiemann
Journal:  Virchows Arch       Date:  2005-08-17       Impact factor: 4.064

5.  PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.

Authors:  C L Rosenberg; E Wong; E M Petty; A E Bale; Y Tsujimoto; N L Harris; A Arnold
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

6.  The value of immunohistochemistry on paraffin wax embedded tissue sections in the differentiation of small lymphocytic and mantle cell lymphomas.

Authors:  N Singh; D H Wright
Journal:  J Clin Pathol       Date:  1997-01       Impact factor: 3.411

7.  New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies.

Authors:  David W Scott; Pau Abrisqueta; George W Wright; Graham W Slack; Anja Mottok; Diego Villa; Pedro Jares; Hilka Rauert-Wunderlich; Cristina Royo; Guillem Clot; Magda Pinyol; Merrill Boyle; Fong Chun Chan; Rita M Braziel; Wing C Chan; Dennis D Weisenburger; James R Cook; Timothy C Greiner; Kai Fu; German Ott; Jan Delabie; Erlend B Smeland; Harald Holte; Elaine S Jaffe; Christian Steidl; Joseph M Connors; Randy D Gascoyne; Andreas Rosenwald; Louis M Staudt; Elias Campo; Lisa M Rimsza
Journal:  J Clin Oncol       Date:  2017-03-14       Impact factor: 44.544

8.  Blastic mantle cell leukemia: a previously undescribed form.

Authors:  C H Dunphy; J C Hancock; J J Rodriguez; J G Hilton
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

9.  Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas.

Authors:  N S Aguilera; K E Bijwaard; B Duncan; A E Krafft; W S Chu; S L Abbondanzo; J H Lichy; J K Taubenberger
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

10.  Potential effects of CRM1 inhibition in mantle cell lymphoma.

Authors:  Ke-Jie Zhang; Michael Wang
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.